AgomAb Therapeutics NV (AGMB) vs Galectin Therapeutics (GALT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
AgomAb Therapeutics NV is the larger company by market cap ($447.2 million vs $397.3 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AGMB | GALT |
|---|---|---|
| Share price | $9.08 | $3.94 |
| Market cap | $447.17M | $397.35M |
| 1-day change | -1.52% | +8.24% |
| YTD return | — | -5.29% |
| 1-year return | — | -17.05% |
| 5-year return | — | +8.01% |
| EPS (TTM) | $-2.08 | $-0.47 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $17.82 | $7.13 |
| 52-week low | $7.97 | $2.03 |
| Distance from 52-week high | -49.05% | -44.74% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +314.87% | +179.19% |
| Average volume | 140.67K | 383.22K |
| Shares outstanding | 49.25M | 100.85M |
| Employees | 62 | 9 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About AgomAb Therapeutics NV
AGMB stock →AgomAb Therapeutics NV, a clinical-stage biopharmaceutical company, develops novel disease-modifying therapies for immunology and inflammatory diseases in the United States. The company's product pipeline includes Ontunisertib (AGMB-129), an oral gastrointestinal-restricted small molecule inhibitor of ALK5 or TGFßR1 for the treatment of Fibrostenosing Crohn's disease, which is in Phase 2a clinical trials; and AGMB-447, an inhaled small molecule inhibitor of ALK5 or TGFßR1 for the treatment of idiopathic pulmonary fibrosis that is in Phase 1 clinical trials.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 62 employees
About Galectin Therapeutics
GALT stock →Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in drug development to create new therapies for fibrotic disease and cancer. The company's lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in a Phase 2 clinical study in MASH patients with advanced fibrosis and a second Phase 2b clinical trial in MASH patients with compensated cirrhosis and portal hypertension.
Health Care · Biotechnology: Pharmaceutical Preparations · 9 employees
AGMB vs GALT FAQ
Which is bigger, AgomAb Therapeutics NV or Galectin Therapeutics?
AgomAb Therapeutics NV (AGMB) is larger, with a market capitalization of $447.17M compared with $397.35M for Galectin Therapeutics (GALT).
Are AgomAb Therapeutics NV and Galectin Therapeutics in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for AgomAb Therapeutics NV and Biotechnology: Pharmaceutical Preparations for Galectin Therapeutics.